NCT04107142 - Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

September 1, 2020

Study Completion Date

March 1, 2021

Conditions

Colorectal CancerTriple Negative Breast CancerSarcomaNasopharyngeal CarcinomaProstate CancerGastric Cancer

Interventions

BIOLOGICAL

Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell

Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)

Trial Locations (1)

Landmark Medical Centre, Johor Bahru